PE Giants Vie for Gland Pharma in USD 3 Billion Blockbuster Buyout

Also Read: Gland Pharma promoter Fosun divests 6 percent stake for Rs 1,754 crore

According to the Moneycontrol report, Fosun is looking to exit Gland Pharma as part of a broader strategy to reduce debt and reallocate resources amid economic and regulatory challenges in China. The deal is attracting significant interest from private equity firms given Gland Pharma’s strong growth trajectory in the global injectables market.

The report further highlights that apart from Blackstone, Brookfield, and Warburg Pincus, other investment firms have also shown preliminary interest in the stake sale. However, the final bidding process is expected to be competitive, given Gland Pharma’s market positioning and its potential for expansion.

Gland Pharma's stock has seen volatility amid reports of the impending sale, reflecting investor sentiment on the potential change in ownership. Market analysts believe that a strategic investor could provide fresh impetus for the company’s expansion, especially in the U.S. and European markets.

The acquisition talks come at a time of heightened scrutiny over Chinese investments in Indian firms, which may influence the regulatory process surrounding the transaction. Given the scale of the deal, it is expected to undergo rigorous scrutiny from the Competition Commission of India (CCI) and other regulatory bodies, reports LiveMint.

Industry insiders suggest that if the deal materializes, it could mark one of the largest private equity transactions in the Indian pharmaceutical sector, underscoring the increasing interest in the country's growing healthcare and pharma industry.